There are currently 167 clinical trials in Boca Raton, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Boca Raton Regional Hospital, Parkinson's Disease and Movement Disorders Center of Boca Raton, GSK Investigational Site and Excel Medical Clinical Trials. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Recruiting
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not worki... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Clearlyderm Dermatology - West Boca /ID# 264963, Boca Raton, Florida
Conditions: Moderate Plaque Psoriasis
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Recruiting
The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%, TPS ≥1% and TPS 1% to 49%; and (2) progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), in participants with PD-L1 TPS ≥1% and TPS ≥50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Boca Raton Regional Hospital ( Site 0004), Boca Raton, Florida
Conditions: Lung Neoplasms, Non-Small-Cell Lung Carcinoma
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
All
Ages:
Between 18 years and 63 years
Trial Updated:
06/19/2024
Locations: Skin Care Research Boca Raton /ID# 263733, Boca Raton, Florida
Conditions: Atopic Dermatitis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/19/2024
Locations: SFM Clinical Research LLC, Boca Raton, Florida
Conditions: Relapsing Multiple Sclerosis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: Skin Care Research Incorporated, Boca Raton, Florida
Conditions: Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/19/2024
Locations: Skin Care Research, Inc, Boca Raton, Florida
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Excel Medical Clinical Trials, Boca Raton, Florida
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: FM Clinical Research, LLC South Florida Neurology Associates, P. A., Boca Raton, Florida
Conditions: Myositis
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: FWD Clinical Research, Boca Raton, Florida
Conditions: Acute Coronary Syndrome
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Recruiting
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Baptist Lynn Cancer Institute, Boca Raton, Florida
Conditions: Carcinoma, Non-small-Cell Lung
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 253733, Boca Raton, Florida
Conditions: Rheumatoid Arthritis
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Neurology Offices of South Florida, PLLC /ID# 257161, Boca Raton, Florida
Conditions: Migraine